Teva Pharmaceuticals Ireland

Lobbying Organisation Teva Pharmaceuticals Ireland

Date published 05 May, 2021

Relevant Matter Matters involving public funds

Public Policy Area Health

Period 1 Jan, 2021 to 30 Apr, 2021

Specific Details Briefing Deputy Alan Kelly on the status of the migraine treatment Fremanezumab and the need for clarity and transparency around timelines for approval for reimbursement.

Intended results A Parliamentary Question on when patients can expect to receive access to Fremanezumab

Name of person primarily responsible for lobbying on this activity Killian Keys, Wilson Hartnell

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) No

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? Yes

Client(s)

Client 1

Company name Teva Pharmaceuticals

CRO number (if applicable)

Company address Digital Office Centre Swords Suite 101-103 Balheary Demense Balheary Road Swords Co. Dublin K67E5AO

Main business or activity Health

Company website www.teva.ie

Contact email address info@teva.ie

Contact phone number 1800-201-700

Contact address

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Email (2-5)

Phone call (1)

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Alan Kelly TD (Dáil Éireann, the Oireachtas)